Liver Cirrhosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta

Liver Cirrhosis Pipeline constitutes 30+ key companies continuously working towards developing 30+ Liver Cirrhosis treatment therapies, analyzes DelveInsight.

Liver Cirrhosis Overview:

Liver cirrhosis is a chronic condition where the liver becomes scarred and permanently damaged, with healthy tissue being replaced by scar tissue, ultimately impairing its normal function. This condition typically results from prolonged liver injury caused by factors such as alcohol-related liver disease, nonalcoholic fatty liver disease, and chronic infections like hepatitis B or C. Symptoms often don't surface until significant liver damage has occurred and may include tiredness, intense itching, and swelling in the legs or abdomen.

Diagnosis of cirrhosis involves evaluating a patient's medical history and conducting a physical examination, along with tests like blood work, imaging (e.g., ultrasound, CT, MRI), and sometimes a liver biopsy to determine the extent of liver damage. While there is no direct cure for cirrhosis, managing the root causes can slow disease progression and help prevent liver failure. Possible complications include portal hypertension, infections, and liver cancer. Lifestyle changes such as maintaining a healthy diet and avoiding harmful substances like alcohol and raw shellfish are crucial in managing the condition. In advanced cases, a liver transplant may be considered.

The symptoms of cirrhosis can vary depending on how advanced the disease is. Early signs may involve fatigue, loss of appetite, weight loss, nausea, abdominal pain, and visible small red blood vessels on the skin (spider angiomas). As the condition worsens, individuals may experience fluid retention in the legs and abdomen, jaundice (yellowing of the skin and eyes), red palms, hormonal imbalances in men (like impotence or breast enlargement), easy bruising, abnormal bleeding, confusion, clay-colored stools, and gastrointestinal bleeding.

Request for a detailed insights report on Liver Cirrhosis pipeline insights @ https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Liver Cirrhosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Liver Cirrhosis Therapeutics Market.

Key Takeaways from the Liver Cirrhosis Pipeline Report

DelveInsight's Liver Cirrhosis pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Liver Cirrhosis treatment.
Key Liver Cirrhosis companies such as Versantis AG, Mirum Pharmaceuticals, Sagimet Biosciences, TenNor Therapeutics, Prism Pharma, Vedanta Biosciences, Lipocine, Gwo Xi Stem Cell Applied Technology, Galectin Therapeutics, Resolution Therapeutics, Ipsen, AstraZeneca, and others are evaluating new drugs for Liver Cirrhosis to improve the treatment landscape.
Promising Liver Cirrhosis pipeline therapies in various stages of development include Elafibranor, AZD2389, PHIN-214, and others.

Recent breakthroughs in the Liver Cirrhosis Pipeline Segment:

In January 2025, Akero Therapeutics reported positive results from a 96-week Phase 2b study of efruxifermin in patients with cirrhosis due to MASH. The study indicated that 39% of patients receiving EFX experienced a reversal of cirrhosis without worsening MASH, compared to 15% in the placebo group.
In November 2024, the FDA declined full approval for Intercept Pharmaceuticals' Ocaliva for treating liver disease, maintaining its status under accelerated approval. Subsequently, in December 2024, the FDA identified cases of liver injury associated with Ocaliva, advising healthcare professionals to discontinue its use in certain patients.
In October 2024, the FDA granted Breakthrough Therapy designation to survodutide, an experimental drug developed by Zealand Pharma and Boehringer Ingelheim, for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). This designation aims to expedite the drug's development and review process.
In August 2024, Gilead Sciences received FDA accelerated approval for Livdelzi to treat PBC. This approval expanded the available treatment options for patients with this rare liver disease.
In June 2024, the FDA granted accelerated approval to Iqirvo for treating primary biliary cholangitis (PBC), a rare liver disease. This approval introduced the first new therapeutic option for PBC in nearly a decade, offering a novel approach to managing this condition.
In March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra for adults with noncirrhotic non-alcoholic steatohepatitis (NASH) accompanied by moderate to advanced liver fibrosis. This approval marked the first treatment specifically targeting this condition, aiming to reduce liver inflammation and scarring.

Liver Cirrhosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Liver Cirrhosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cirrhosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Liver Cirrhosis market.

Download our free sample page report on Liver Cirrhosis pipeline insights @ https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Liver Cirrhosis Emerging Drugs

Elafibranor: Ipsen
AZD2389: AstraZeneca
PHIN-214: PharmaIN

Liver Cirrhosis Companies

Over 30 notable companies are actively working on developing treatments for liver cirrhosis. Among them, Ipsen has a drug candidate that has progressed to the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Liver Cirrhosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Liver Cirrhosis Therapies and Key Companies: Liver Cirrhosis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Liver Cirrhosis Pipeline Therapeutic Assessment
• Liver Cirrhosis Assessment by Product Type
• Liver Cirrhosis By Stage
• Liver Cirrhosis Assessment by Route of Administration
• Liver Cirrhosis Assessment by Molecule Type

Download Liver Cirrhosis Sample report to know in detail about the Liver Cirrhosis treatment market @ Liver Cirrhosis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Liver Cirrhosis Current Treatment Patterns
4. Liver Cirrhosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Liver Cirrhosis Late-Stage Products (Phase-III)
7. Liver Cirrhosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Liver Cirrhosis Discontinued Products
13. Liver Cirrhosis Product Profiles
14. Liver Cirrhosis Key Companies
15. Liver Cirrhosis Key Products
16. Dormant and Discontinued Products
17. Liver Cirrhosis Unmet Needs
18. Liver Cirrhosis Future Perspectives
19. Liver Cirrhosis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Liver Cirrhosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.